Delving into the Latest Updates on Guangzhou Shunjian Biomedical Technology Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Bcr-Abl T315I x c-Kit	1

主要目的：评价慢性髓性白血病患者高脂餐后单次口服HQP1351片药代动力学特点；评价慢性髓性白血病患者空腹单次口服HQP1351的药代动力学（PK）特点。次要目的：评估慢性髓性白血病患者空腹和餐后单次口服HQP1351的安全性和耐受性。

[Translation]

Primary objective: To evaluate the pharmacokinetic characteristics of HQP1351 tablets after a single oral administration of a high-fat meal in patients with chronic myeloid leukemia; to evaluate the pharmacokinetic (PK) characteristics of HQP1351 tablets after a single oral administration on an empty stomach in patients with chronic myeloid leukemia. Secondary objective: To evaluate the safety and tolerability of HQP1351 tablets after a single oral administration on an empty stomach and after a meal in patients with chronic myeloid leukemia.

Start Date25 Mar 2019

Sponsor / Collaborator

Guangzhou Shunjian Biomedical Technology Co. Ltd.

CTR20160654

/ CompletedPhase 1

HQP1351治疗酪氨酸激酶抑制剂耐药的慢性髓性白血病患者的剂量递增的Ⅰ期临床试验

[Translation] Phase I clinical trial of HQP1351 in the treatment of patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors

主要目的：确定HQP1351治疗TKI耐药的慢性髓性白血病患者的最大耐受剂量，或Ⅱ期临床推荐剂量（RP2D）。次要目的：评估HQP1351治疗TKI耐药的慢性髓性白血病患者的安全性。评估HQP1351治疗TKI耐药的慢性髓性白血病患者的疗效。评估HQP1351体内的药代动力学特征。探索性目的：探讨HQP1351潜在的生物标志物与疗效的相关性。

[Translation]

Primary objective: To determine the maximum tolerated dose of HQP1351 for the treatment of TKI-resistant chronic myeloid leukemia patients, or the recommended dose for phase II clinical trials (RP2D). Secondary objective: To evaluate the safety of HQP1351 in the treatment of TKI-resistant chronic myeloid leukemia patients. To evaluate the efficacy of HQP1351 in the treatment of TKI-resistant chronic myeloid leukemia patients. To evaluate the pharmacokinetic characteristics of HQP1351 in vivo. Exploratory objective: To explore the correlation between potential biomarkers of HQP1351 and efficacy.

Start Date17 Oct 2016

Sponsor / Collaborator

Guangzhou Shunjian Biomedical Technology Co. Ltd.

ChiCTR1900027568

/ RecruitingPhase 1IIT

Phase I Dose Escalation Study of HQP1351 on Tyrosine Kinase Inhibitor (TKI) Resistant Patients with Chronic Myelogenous Leukemia

Start Date04 Aug 2016

Sponsor / Collaborator

Peking University People's Hospital

[+1]

100 Clinical Results associated with Guangzhou Shunjian Biomedical Technology Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Shunjian Biomedical Technology Co. Ltd.

Login to view more data

100 Deals associated with Guangzhou Shunjian Biomedical Technology Co. Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Shunjian Biomedical Technology Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Olverembatinib ( Bcr-Abl T315I x c-Kit )	Philadelphia positive acute lymphocytic leukaemia More	Phase 3
HQP8361 ( MST1R x c-Met )	Advanced Malignant Solid Neoplasm More	Pending